The stock of Akoya Biosciences Inc (NASDAQ:AKYA) last traded at $1.26, down -3.08% from the previous session.
AKYA stock price is now -0.66% away from the 50-day moving average and -42.97% away from the 200-day moving average. The market capitalization of the company currently stands at $62.84M.
With the price target reduced from $7 to $5, Craig Hallum Downgraded its rating from Buy to Hold for Akoya Biosciences Inc (NASDAQ: AKYA). , while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, McKelligon Brian, President and CEO sold 7,500 shares of the company’s stock on Jun 11 ’24. The stock was sold for $15,630 at an average price of $2.08. Upon completion of the transaction, the President and CEO now directly owns 224,733 shares in the company, valued at $0.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 06 ’24, President and CEO McKelligon Brian sold 7,500 shares of the business’s stock. A total of $15,064 was realized by selling the stock at an average price of $2.01. This leaves the insider owning 224,733 shares of the company worth $0.28 million. A total of 58.29% of the company’s stock is owned by insiders.
During the past 12 months, Akoya Biosciences Inc has had a low of $0.93 and a high of $3.42. The fifty day moving average price for AKYA is $1.26842 and a two-hundred day moving average price translates $2.20943 for the stock.
The latest earnings results from Akoya Biosciences Inc (NASDAQ: AKYA) was released for 2025-03-31. The net profit margin was -59.45% and return on equity was -354.27% for AKYA. The company reported revenue of $16.64 million for the quarter, compared to $18.35 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -9.32 percent.
